Keynote review: Disease-specific target selection: A critical first step down the right road

Drug Discovery Today

Volumn 10, Issue 3, 2005, Pages 177-189

  Roses, Allen D ^a   Burns, Daniel K ^a   Chissoe, Stephanie ^a   Middleton, Lefkos ^b   St Jean, Pamela ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDIABETIC AGENT;

ASTHMA; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC TEST; DRUG BIOAVAILABILITY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EMPIRICISM; EXPERIMENTAL TEST; FUTUROLOGY; GENE FREQUENCY; GENE SEQUENCE; GENE TARGETING; GENETIC LINKAGE; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; KNOCKOUT GENE; METABOLIC SYNDROME X; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PROBABILITY; REVIEW; SCREENING TEST; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; VALIDATION PROCESS; DRUG DESIGN; GENETICS; GENOMICS; METHODOLOGY; PHARMACEUTICS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICS;

ASTHMA; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; GENOMICS; HUMANS; METABOLIC SYNDROME X; POLYMORPHISM, SINGLE NUCLEOTIDE; STATISTICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 13544270007     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03321-5     Document Type: Review

References (60)

1. Chapman T. Drug discovery - the leading edge. Nature. 430:2004;109
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:2004;711-715
3. Roses A. Genome-based pharmacogenetics and the pharmaceutical industry. Nat. Rev. Drug Discov. 1:2002;541-549
4. Aono S., et al. Analysis of genes for bilirubin UDP- glucuronosyltransferase in Gilbert's syndrome. Lancet. 345:1995;958-959
5. Fijal B.A., et al. Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial. Control. Clin. Trials. 21:2000;7-20
6. Monaghan G., et al. Genetic variation in bilirubin UPD- glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 347:1996;578-581
7. Chanda S., Caldwell J. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today. 8:2003;168-174
8. Glassman R., Sun A. Biotechnology: identifying advances from the hype. Nat. Rev. Drug Discov. 3:2004;177-183
9. Johnston P.A., Johnston P.A. Cellular platforms for HTS: three case studies. Drug Discov. Today. 7:2002;353-363
10. Austin C.P., et al. The knockout mouse project. Nat. Genet. 36:2004;921-924
11. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964
12. Marecki S., Kirkpatrick P. Efalizumab. Nat. Rev. Drug Discov. 3:2004;473-474
13. Food and Drug Administration (2004) Innovation stagnation, challenge and opportunity on the critical path to new medical products (http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html)
14. Berns A. Cancer - improved mouse models. Nature. 410:2001;1043-1044
15. Liggett S.B. Opinion: genetically modified mouse models for pharmacogenomic research. Nat. Rev. Genet. 5:2004;657-663
16. Zambrowicz B.P., et al. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr. Opin. Pharmacol. 3:2003;563-570
17. Zambrowicz B.P., Sands A. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. 2:2003;38-51
18. Hirschhorn J., et al. A comprehensive review of genetic association studies. Genet. Med. 4:2002;45-61
19. Neale B., Sham P. The future of association studies: gene-based analysis and replication. Am. J. Hum. Genet. 75:2004;353-362
20. Lohmueller K., et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33:2003;177-182
21. Ioannidis J., et al. Genetic associations in large versus small studies: an empirical assessment. Lancet. 361:2003;567-571
22. Tabor H.K., et al. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat. Rev. Genet. 3:2002;391-397
23. Thomas D., Clayton D. Betting odds and genetic associations. J. Natl. Cancer Inst. 96:2004;421-423
24. Weiss K., Terwilliger J. How many diseases does it take to map a gene with SNPs. Nat. Genet. 26:2000;151-157
25. Risch N. Searching for genetic determinants in the new millennium. Nature. 405:2000;847-856
26. Colhoun H.M., et al. Problems of reporting genetic associations with complex outcomes. Lancet. 361:2003;865-872
27. Tufts Center for the Study of Drug Development (2003) Post-approval R&D raises total drug development costs to $897 million. Impact Report: Analysis and Insight into Critical Drug Development Issues 5, May-June
28. Venter J.C. Genomic impact on pharmaceutical development. Novartis Foundation Symposium. 229:2000;14-18
29. Collins F., McKusick V. Implications of the Human Genome Project for medical science. J. Am. Med. Assoc. 285:2001;540-544
30. Lander E., et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921
31. Venter J., et al. The sequence of the human genome. Science. 291:2001;1304
32. Fishman M.C. An audience with. Nat. Rev. Drug Discov. 3:2004;292
33. Lindsay M. Innovation - target discovery. Nat. Rev. Drug Discov. 2:2003;831-838
34. Goldstein D., et al. Pharmacogenetics goes genomic. Nat. Rev. Genet. 4:2003;937-947
35. Altshuler D., et al. The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26:2000;76-80
36. Martin E., et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. J. Am. Med. Assoc. 286:2001;2245-2250
37. Van Eerdewegh P., et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 418:2002;426-430
38. Funke B., et al. Association of the DTNBP1 Locus with Schizophrenia in a U.S. Population. Am. J. Hum. Genet. 75:2004;891-898
39. Duan J., et al. Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia. Am. J. Hum. Genet. 75:2004;624-638
40. Giallourakis C., et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am. J. Hum. Genet. 73:2003;205-211
41. Schmith V., et al. Pharmacogenetics and disease genetics of complex diseases. Cell. Mol. Life Sci. 60:2003;1636-1646
42. Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14:1996;1516-1518
43. Hopkins A.L., Groom C. The druggable genome. Nat. Rev. Drug Discov. 1:2002;727-730
44. Sachidanandam R., et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 409:2001;928-933
45. Wyszynski, D.F. et al. The relationship between atherogenic dyslipidemia and the adult treatment program-III definition of metabolic syndrome: The Genetic Epidemiology of Metabolic Syndrome Project. Am. J. Cardiol (in press)
46. Taylor J.D., et al. Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques. 30:2001;661-669
47. Chen J., et al. A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension. Genome Res. 10:2000;549-557
48. Mehta C., Patel N. A network algorithm for performing Fisher's Exact Test in r×c contingency tables. J. Am. Stat. Assoc. 78:1983;427-434
49. Neale B., Sham P. The future of association studies: gene-based analysis and replication. Am. J. Hum. Genet. 75:2004;353-362
50. Cardon L., Bell J. Association study designs for complex diseases. Nat. Rev. Genet. 2:2001;91-99
51. Roses A. SNPs - where's the beef? Pharmacogenomics J. 2:2002;277-283
52. McCarthy L., et al. Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics. 78:2001;135-149
53. Hewett D., et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics. 79:2002;305-314
54. Martin E., et al. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am. J. Hum. Genet. 67:2000;146-154
55. Rioux J., et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. 29:2001;223-228
56. Carlson C., et al. Mapping complex disease loci in whole-genome association studies. Nature. 429:2004;446-452
57. North B.V., et al. A note on the calculation of empirical P values from Monte Carlo procedures. Am. J. Hum. Genet. 71:2002;439-441
58. Davison A.C., Hinkley D.V. The Basic Bootstraps. Gill R,, et al. Bootstrap Methods and their Application. 1997;11-66 Cambridge University Press
59. Davison A.C., Hinkley D.V. Tests. Gill R,, et al. Bootstrap Methods and their Application. 1997;136-187 Cambridge University Press
60. Roses A. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5:2004;645-655